🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million new cases per year. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone represents a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

Based on data released by a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The trial included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have expressed optimism. Having a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the illness for patients and to prevent the spread of extremely resistant gonorrhoea globally.